With a 52% increase in patent filings and a 160% jump in research publications, the RNA technology field has exploded in the last 10 to 12 years, and the U.S. and mainland China are paving the way. Identifying seven emerging RNA innovators, Clarivate plc’s RNA Technology Companies to Watch is a new report that harnesses data and insights from both Clarivate and BioWorld.

Approval of a new depression drug, stellar phase III data for both a schizophrenia therapy and an Alzheimer’s disease candidate, as well as an accelerated approval filing for a Duchenne muscular dystrophy gene therapy, are all reasons that BioWorld’s Neurological Diseases Index climbed from a negative position throughout much of 2022 to its 11% above-water mark as of Oct. 20.

The value of med-tech mergers and acquisitions, as well as deals, fell in the third quarter, although 2022 remains a standout year. M&As are at a five-year high, while deals are second only to 2019, in terms of overall value during the first three quarters. The volume of M&As are behind 2021, but deal volume this year remains on top.